WIVI Vision is 5 times more affordable for prescribers and 10 times more affordable for the user.
Visual function is the integration of how our vision interacts with the world, how we interpret and encode the information from our brains to respond to any type of visual stimulus. We receive more than 85% of the information of our environment through our vision. Any alteration of this process could limit our relationship with the environment, especially in the early stages of life when the majority of our personal development happens.
The visual process can be divided into three stages. Until today, optometric examinations have focused mainly on the first and second stages; obtaining a clear image in the retina without considering factors such as performance or efficiency of the visual system. Lack of an objective and accurate control, along with highly priced sessions are also some of the factors that highlight the need of a more efficient system. Moreover, current instruments only work independently with regard to the parameters of the visual functions.
WIVI Vision is the first device that integrates the clinical and technological aspects of the visual function treatment, providing information for the specialist with objective measurement in real time. Fifty ocular parameters directed to the visual functions are measured at the same time, with freedom of movement and control of the user
WIVI is 10 times cheaper for the user, 5 times cheaper for the prescriber, and 5 times more motivating and faster than what are currently done manually and subjectively. Virtual reality and immersive environments are adapted to improve visual function as the user interacts and carries out visual challenges.
This patented system allows to the prescribers: optical shops and ophthalmologic clinics to increase their service portfolio and their revenues, with assessment and training sessions that can be easily carried out in reduced times. The collaboration with prescribers has made this possible. Specifically, the treatment period is reduced by 60%, while each session duration will be 75% shorter than the current optometric therapies.